NCT02661126View on ClinicalTrials.gov

Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 19, 2016

Primary Completion Date

August 26, 2016

Study Completion Date

August 26, 2016

Conditions
Hepatitis C
Interventions
DRUG

MK-3682B

FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02661126 - Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) | Biotech Hunter | Biotech Hunter